Genmab A/S (GNMSF) Stock Price & Analysis
Genmab A/S (GNMSF) — price $521.80 (+1.32%), as of the Nov 19, 2026 trading session; market cap $32.2B.
Educational signal · not a buy or sell recommendation · How to read this
Genmab A/S · GNMSF · Healthcare · Biotechnology
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $521.80 | |
| Change on the day | +1.32% | |
| 52-week range | $232.34–$581.00 | |
| Market capitalisation | $32.2B | — |
| Price / earnings (trailing) | 43.33 | |
| Shares traded on the day | 2 | |
| Beta (volatility vs the S&P 500) | 0.66 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Genmab A/S (GNMSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Genmab A/S (GNMSF), and what does it report?
Short answer
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. Genmab A/S (GNMSF) is classified as Healthcare / Biotechnology. SEC filing business address: Toldbodgade 33, 1253 Copenhagen K, G7, 00000. It employs 3,029 people and is led by Jan van de Winkel. In Q3 FY2026 it reported revenue of $1.19B and net income of $342M. The market values it at $32.2B.
What do the latest results show for Genmab A/S (GNMSF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.19B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.19B | $342M | $5.51 (diluted) |
| Q2 FY2026 | $1.13B | $297M | $4.81 (diluted) |
| Q1 FY2026 | $896M | $53M | $0.83 (diluted) |
| Q4 FY2025 | $1.06B | $31M | $0.46 (diluted) |
What are the financial strengths and risks for Genmab A/S (GNMSF)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 20.96 · Piotroski F 5. Trailing ratios: ROE 12.1% · ROA 8.2% · current ratio 2.45.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GNMSF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GNMSF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Genmab A/S (GNMSF) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the GNMSF research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is GNMSF a good stock to buy?
Stock Expert AI does not rate GNMSF buy, sell or hold. Genmab A/S has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GNMSF stock price today?
The last price recorded for Genmab A/S (GNMSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Genmab A/S do?
Genmab A/S is a biotechnology company focused on the creation and development of antibody therapeutics for the treatment of cancer and other diseases.
What are the key factors to evaluate for GNMSF?
Evaluate GNMSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. The drug is currently under review by regulatory agencies. Not financial advice.
How frequently does GNMSF data refresh on this page?
GNMSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GNMSF's recent stock price performance?
Genmab A/S (GNMSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody therapeutics platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNMSF overvalued or undervalued right now?
The trailing P/E of Genmab A/S (GNMSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNMSF before investing?
Before investing in Genmab A/S (GNMSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com